SCHEMBL2586743

SCHEMBL2586743

Cc1c(P(=S)(c2ccccc2)c2ccccc2)c2ccccc2n1CCCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 14/20 0.58
CNR2 P34972 2/20 0.45
SIGMAR1 Q99720 1/20 0.45
CNR1 P21554 1/20 0.45
PLA2G2A P14555 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2593998 0.93 NPSR1 (0.63) NPSR1CNR2CNR1ALDH1A1
SCHEMBL2587268 0.85 NPSR1 (0.63) NPSR1PLA2G2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL17278442 0.76 SIGMAR1 (0.62) SIGMAR1
SCHEMBL2595693 0.75 NPSR1 (1.00) NPSR1KDM4EALDH1A1TDP1
SCHEMBL2594863 0.74 NPSR1 (1.00) NPSR1SIGMAR1
SCHEMBL2594864 0.74 NPSR1 (1.00) NPSR1SIGMAR1
SCHEMBL15489575 0.71 FABP4 (0.59) SIGMAR1
SCHEMBL388824 0.69 MEN1 (0.69) SIGMAR1KDM4EALDH1A1SMN1; SMN2TDP1
SCHEMBL15126342 0.69 CNR2 (0.62) CNR2CNR1SMN1; SMN2
SCHEMBL2590909 0.69 NPSR1 (1.00) NPSR1KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011137220-A1 SMALL MOLECULE NEUROPEPTIDE S ANTAGONISTS FOR THE TREATMENT OF ADDICTIVE DISORDERS, MOOD, ANXIETY AND SLEEP DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-11-03 WO disclosed
WO-2011137220-A1 SMALL MOLECULE NEUROPEPTIDE S ANTAGONISTS FOR THE TREATMENT OF ADDICTIVE DISORDERS, MOOD, ANXIETY AND SLEEP DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-11-03 WO disclosed